|

BNGO Stock Forecast: BioNano Genomics Inc boosted by DNA study

  • NASDAQ: BNGO has soared by 14% on Tuesday to $12.16.
  • BioNano Genomics announced publication of a study on DNA methylation.
  • BNGO is one of the best performing stocks of 2021.

Update: BNGO shares are trading higher on Tuesday as the company announced that its "Saphyr Study Is First to Analyze Cancer Regulation at Level of Single DNA Molecules, Opens Promising New Avenue of Cancer Research". 

Going from strength to strength – BioNano Genomics (NASDAQ: BNGO) has surged by 28.73% on Monday, closing at $12.58. While shares are off the fresh 52-week highs of $13.65 and may continue correcting on Tuesday, the surge is an incredible feat for the firm. San Diego-based Bioano hit a 52-week low of $0.25 late last year, making its leap even more impressive.

The genetics company impressed the medical community and investors with its recent breakthroughs including mapping genes related to the autism spectrum, cancer, and even COVID-19. Its work allows for better care and may also translate into higher sales down the road. 

Investors were impressed enough to provide the company with $230 million in its underwritten offering of common stock. The financial exercise includes options to buy more stocks at a discounted price. The prospects of offering new stock had already weighed on BNGO earlier in the year, and closing the round was shrugged off on Monday. 

Raising money became easier when professional investors also gave BioNano Genomics some backing. Jason McCarthy, an analyst with Maxim, bumped up his price forecast from $2 to $14. At the current closing price, there is still room for the company to run. McCarthy was impressed by the firm's Next-Generation Cytogenomics Symposium – an event where it showcased its Saphyr optical genome mapping (OGM)  capabilities. 

BNGO stock price

NASDAQ: BNGO has already dropped from the highs and may continue lower. However, such a correction makes sense after the meteoric rise. To the downside, the levels to watch are the round $12 level and then Monday's low of $10.45. 

Looking up, Monday's close at $12.58 is followed by $13 and then by $13.65, the 52-week high. McCarthy's price forecast of $14 is next in line. 

Best Stocks to Buy Forecast 2021: Vaccines and zero rates to broaden recovery

Author

Yohay Elam

Yohay Elam

FXStreet

Yohay is in Forex since 2008 when he founded Forex Crunch, a blog crafted in his free time that turned into a fully-fledged currency website later sold to Finixio.

More from Yohay Elam
Share:

Editor's Picks

GBP/USD extends the drop to 1.3360

GBP/USD builds on Monday’s decline and briefly clinches five-day lows near 1.3360 on Tuesday. Cable’s extra pullback follows the better tone in the Greenback as uncertainty in the Middle East prompts investors to adopt a cautious stance. Meanwhile, an apathetic UK labour market report also collaborates with the selling pressure on the British Pound.

EUR/USD stays offered just above 1.1400

EUR/USD keeps the downtrend well in place for yet another day, challenging the 1.1400 contention zone on Tuesday. The continuation of the selling impulse in spot comes amid decent gains in the US Dollar, which continues to find support in the persistent effervescence surrounding the US-Iran crisis.

Middle East crisis intensifies, Gold up

Gold now seems to have embarked on a consolidative phase below the key $4,100 mark per troy ounce in the latter part of Tuesday’s session. Meanwhile, uncertainty surrounding the Middle East conflict and rising expectations for a hawkish Fed policy outlook are expected to limit the precious metal’s bullish momentum in the near term.

XRP rebounds on rising on-chain activity
Ripple (XRP) ticks up and trades around $1.13 at the time of writing on Tuesday. This rebound aligns with a broader recovery in the cryptocurrency market, attributed to reports that mediators between the United States (US) and Iran are seeking a 10-day cessation of strikes to find a way back to the signed Memorandum of Understanding (MoU).
The Iranian war has again risen
The Iranian war has again risen to the top of the economics factor list. There is no end in sight. Intelligence experts say the current level of offense/retaliation will not change minds in Tehran, while in Washington, Trump fears all-out war, which would mean boots on the ground.
US Dollar mid-year outlook: Exceptional currency, exceptional risks?
The US Dollar enters the second half of 2026 in a markedly different position from a year ago. The King currency has recovered, reflecting persistent US inflation, changing expectations for Fed policy, geopolitical tensions and renewed demand for defensive assets.